This raises to five the number of businesses in the biotech-pharmaceuticals sector admitted to Euronext markets since the beginning of the year. The two newcomers follow Galapagos on Eurolist Amsterdam and Brussels, Devgen on Eurolist Brussels, and ExonHit Therapeutics on Alternext.
Ipsen placed 14.6 million shares to raise EUR 323 million, and BioAlliance Pharma 2.25 million shares raising EUR 30 million.
Based on their reference price, the two transactions increased the market capitalization of Euronext markets by EUR 1.94 billion, including EUR 1.83 billion for Ipsen and EUR 110 million for BioAlliance Pharma.
Altogether, Euronext markets have welcomed 65 listings since January 2005, for shares representing EUR 17 billion and adding EUR 104 billion to total market capitalization.
Ipsen ISIN code: FR0010259150
BioAlliance Pharma ISIN code: FR0010095596
Founded in 1929, Ipsen is a European pharmaceuticals business that now sells over 20 drugs including treatments marketed around the world to specialists in oncology, endocrinology and neuromuscular disorders, its primary areas of development. The Group also markets products in other therapeutic areas in which it boasts longstanding expertise (gastroenterology, cardiovascular and cognitive disorders). Most of these are sold to general practitioners in France.
BioAlliance Pharma is a biopharmaceutical company specialized in the development of innovative therapeutics to overcome drug resistance, notably through improved patient compliance and targeted delivery of active ingredients.
